FOXO1 belongs to the very large Forkhead family of transcription factors which contain a conserved distinct DNA-binding domain known as the Forkhead Box, or FOX. The Forkhead domain is a 100 amino acid long motif capable of binding and bending DNA, and is also known as a “winged helix”. Forkhead family members are involved in a very diverse and wide range of physiological processes from cell cycle, apoptosis, and oxidative-stress resistance. The “O” class of proteins in particular are all regulated by the insulin/PI3K/AKT pathway. The 70 kD FOXO1 protein can act as either a coactivator or a corepressor of nuclear receptor activity. This activity is mediated through a LXXLL motif within the C-terminus of FOXO1. While the specific function of FOXO1 has not yet been determined, it appears to play a role in myogenic growth and differentiation, and translocation of this gene with PAX3 has been associated with alveolar rhabdomyosarcoma. In fact, FOXO genes were initially discovered in humans because of such chromosomal translocations in diseases such as rhabdomyosarcomas and acute myeloid leukemias (AMLs).
Immunohistochemistry-Paraffin: FoxO1/FKHR Antibody (83N7F8) [NBP2-31376] - IHC-P analysis of FOXO1A protein in a section of normal human uterus by using FOXO1A antibody at a concentration of 5 ug/ml.
Northwestern University researchers employed the FOXO1 antibody in their explorations of how the progesterone receptor modulates FOXO1 expression and activity in endometrial cancer (1). They will be using their finding that increased FOXO1 expression is progesterone receptor B (PRB)-dependent to develop alternative endometrial cancer therapies. A 2009 paper also cited the used of the FOXO1 antibody to examine progestin downstream AKT signaling in uterine leiomyoma cells (2). Amin et al relied upon the FOXO1 antibody to identify interesting crosstalk between the FOXO1 and p53 signaling networks in concanavalin A-induced apoptosis (3). Immunohistochemistry with the FOXO1 antibody enabled Erovic's group in Toronto to create a comprehensive study of 41 predictive and prognostic markers for medullary thyroid carcinoma (4). Their studies used tissue microarrays in hopes of identifying and profiling novel markers for the systemic adjuvant treatment of patients with advanced disease. A 2014 Nature Medicine publication from Savai's lab at the Max-Planck Institute cited use of the FOXO1 antibody in their explorations of pro-proliferative and inflammatory signaling in pulmonary hypertension (5).
Novus Biologicals offers FOXO1/FKHR reagents for your research needs including: